Skip to main content

Table 5 Comparison of the clinical evaluation

From: A comparison of ARMS and direct sequencing for EGFR mutation analysis and Tyrosine Kinase Inhibitors treatment prediction in body fluid samples of Non-Small-Cell Lung Cancer patients

  Pleural fluid Plasma
  Sequencing ADx-ARMS Sequencing ADx-ARMS
Mutation
positive
Number (%) 16(50%) 22(68.8%) 0 5(27.8%)
  PR 13 16 0 4
  SD 2 5 0 0
  PD 1 1 0 1
  ORR 81.3%a 72.7%c NA 80%e
Mutation negative Number (%) 16(50%) 10(31.2%) 18(100%) 13(72.2%)
  PR 9 6 10 6
  SD 4 1 1 1
  PD 3 3 7 6
  ORR 56.3%b 60%d 55.6% 46.2%f
  1. PR = Partial Response; SD = Stable Disease; PD = Progressive Disease; ORR = Objective response rate
  2. Between a and b, P = 0.2524; Between c and d, P = 0.6828; Between e and f, P = 0.3137; Between a and c, P = 0.706